ZafirlukastCAS# 107753-78-6 |
- VX-765
Catalog No.:BCC3648
CAS No.:273404-37-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 107753-78-6 | SDF | Download SDF |
| PubChem ID | 5717 | Appearance | Powder |
| Formula | C31H33N3O6S | M.Wt | 575.68 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | ICI 204219 | ||
| Solubility | DMSO : 100 mg/mL (173.71 mM; Need ultrasonic) | ||
| Chemical Name | cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate | ||
| SMILES | CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC | ||
| Standard InChIKey | YEEZWCHGZNKEEK-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Zafirlukast is a potent orally active leukotriene D4 (LTD4) receptor antagonist.In Vivo:Zafirlukast is a peptidyl leukotriene antagonist and inhibitor of LTD4. After 13 weeks of exposure, the yield of lung tumors is significantly decreased by both dose levels of Zafirlukast (270 and 540 mg/kg), the high dose of Zileuton (1200 mg/kg), and the combinations containing 600 mg/kg Zileuton with either Zafirlukast or MK-866. The efficacy of the combination containing Zileuton and Zafirlukast to prevent lung tumors is not significantly different from the efficacy of either inhibitor administered alone. Although when administered alone at the dose level in their combination, neither Zileuton or MK-886 prevents lung tumors; the combination containing them does significantly prevent tumors. In contrast, the combination containing Zafirlukast and MK-886 does not reduce the yield of tumors, whereas Zafirlukast administered alone does significantly reduce the yield of tumors[2]. References: | |||||
Zafirlukast Dilution Calculator
Zafirlukast Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7371 mL | 8.6854 mL | 17.3708 mL | 34.7415 mL | 43.4269 mL |
| 5 mM | 0.3474 mL | 1.7371 mL | 3.4742 mL | 6.9483 mL | 8.6854 mL |
| 10 mM | 0.1737 mL | 0.8685 mL | 1.7371 mL | 3.4742 mL | 4.3427 mL |
| 50 mM | 0.0347 mL | 0.1737 mL | 0.3474 mL | 0.6948 mL | 0.8685 mL |
| 100 mM | 0.0174 mL | 0.0869 mL | 0.1737 mL | 0.3474 mL | 0.4343 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Zafirlukast is a leukotriene receptor antagonist (LTRA). (IC50=0.6 uM, IC50=7.0 uM for CYP2C9)
- Methyl 7beta,15-dihydroxydehydroabietate
Catalog No.:BCN7270
CAS No.:107752-10-3
- Epleremone
Catalog No.:BCC3776
CAS No.:107724-20-9
- MDL 11,939
Catalog No.:BCC6822
CAS No.:107703-78-6
- beta-Lipoic acid
Catalog No.:BCC9198
CAS No.:6992-30-9
- Merucathine
Catalog No.:BCN1782
CAS No.:107673-74-5
- Bulleyaconitine A
Catalog No.:BCN1210
CAS No.:107668-79-1
- Merucathinone
Catalog No.:BCN1783
CAS No.:107638-80-2
- Erycibelline
Catalog No.:BCN1876
CAS No.:107633-95-4
- Dehydroformouregine
Catalog No.:BCN4054
CAS No.:107633-69-2
- PF 998425
Catalog No.:BCC7811
CAS No.:1076225-27-8
- 4-Hydroxycoumarin
Catalog No.:BCN2561
CAS No.:1076-38-6
- 4-Demethyl-3,9-dihydroeucomin
Catalog No.:BCN5876
CAS No.:107585-77-3
- A 61603 hydrobromide
Catalog No.:BCC6912
CAS No.:107756-30-9
- Coccinic acid
Catalog No.:BCN5877
CAS No.:107783-45-9
- 3,4-Dihydroxybenzenepropanoic acid
Catalog No.:BCN8500
CAS No.:1078-61-1
- PF 04418948
Catalog No.:BCC6299
CAS No.:1078166-57-0
- Exemestane
Catalog No.:BCC1061
CAS No.:107868-30-4
- Quinovin
Catalog No.:BCN5878
CAS No.:107870-05-3
- Dehydrodiconiferyl alcohol 4-O-beta-D-glucopyranoside
Catalog No.:BCN7707
CAS No.:107870-88-2
- Japonicones D
Catalog No.:BCN3614
CAS No.:1078711-42-8
- Isoeleutherin
Catalog No.:BCN8315
CAS No.:1078723-14-4
- Ganodermanondiol
Catalog No.:BCN5879
CAS No.:107900-76-5
- Sibiricose A5
Catalog No.:BCN2785
CAS No.:107912-97-0
- 9,9-Bis(4-amino-3-methylphenyl)fluorene
Catalog No.:BCC8794
CAS No.:107934-60-1
Zafirlukast: Chronic Urticaria.[Pubmed:27729674]
Hosp Pharm. 2015 Nov;50(10):873-875.
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.[Pubmed:27260089]
Eur J Pharm Sci. 2016 Aug 25;91:31-9.
Poor water solubility is a bottle neck in the development of many new drug candidates, and understanding and circumventing this is essential for a more effective drug development. Zafirlukast (ZA) is a leukotriene antagonist marketed for the treatment of asthma (Accolate(R)). ZA is poorly water soluble, and is formulated in an amorphous form (aZA) to improve its solubility and oral bioavailability. It has been shown that upon dissolution of aZa, the concentration of ZA in solution is supersaturated with respect to its stable crystalline form (ZA monohydrate), and thus, in theory, the bioavailability increases upon amorphization of ZA. The polymers hydroxypropylmethylcellulose (HPMC) and polyvinylpyrrolidone (PVP), often used as stabilizers of the supersaturated state, are in the excipient list of Accolate(R). It is not recommended to take Accolate(R) with food, as this reduces the bioavailability by 40%. The aim of this study was to investigate the effect of simulated fasted and fed state intestinal media as well as the effect of HPMC and PVP on the supersaturation and precipitation of ZA in vitro. Supersaturation of aZA was studied in vitro in a small scale setup using the muDiss Profiler. Several media were used for this study: One medium simulating the fasted state intestinal fluids and three media simulating different fed state intestinal fluids. Solid state changes of the drug were investigated by small angle x-ray scattering. The duration wherein aZA was maintained at a supersaturated state was prolonged in the presence of HPMC and lasted more than 20h in the presence of PVP in a fasted state intestinal medium. The presence of PVP increased the concentration of drug dissolved in the supersaturated state. The duration of supersaturation was shorter in fed than in a fasted state simulated intestinal media, but the concentration during supersaturation was higher. It was thus not possible to predict any positive or negative food effects from the dissolution/precipitation curves from different media. Lipolysis products in the fed state simulated media seemed to cause both a negative effect on the duration of supersaturation, and an increased drug concentration during supersaturation. In contrast, when testing the effect of a fed state simulated medium compared to the fasted state medium, in the presence of PVP, a clear negative effect was seen on the dissolution/precipitation curved of the fed state medium. The drug concentration during supersaturation was marginally different in the two media, but a precipitation of ZA was seen in the fed state medium, which was not observed in the fasted state medium. Solid state transformation from aZA to ZA monohydrate (mhZA) upon precipitation of the supersaturated solutions was confirmed by small angle x-ray scattering. All of these results can explain the described in vivo behavior of ZA. For ZA simple dissolution experiments in vitro can be used to examine supersaturation, effectiveness of PI and potential food effects on these.
In vitro activity of the antiasthmatic drug zafirlukast against the oral pathogens Porphyromonas gingivalis and Streptococcus mutans.[Pubmed:28087617]
FEMS Microbiol Lett. 2017 Jan 1;364(2). pii: fnx005.
Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long-term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the antiasthma drug Zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that Zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of Zafirlukast to be used as a new antibiotic against oral pathogens.
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast.[Pubmed:27377818]
Arch Pharm Res. 2016 Jul;39(7):1013-9.
Zafirlukast, a cysteinyl leukotriene receptor antagonist, is indicated for the treatment of patients with mild to moderate asthma. Zafirlukast is metabolized mainly by CYP3A4 and CYP2C9. We investigated the effects of the major CYP2C9 variant alleles in Asian populations, CYP2C9*3 and CYP2C9*13, on the pharmacokinetics of Zafirlukast in healthy Korean subjects. A single 20-mg oral dose of Zafirlukast was given to 23 Korean male subjects divided into two genotype groups according to CYP2C9 genotypes, CYP2C9EM (n = 11; CYP2C9*1/*1) and CYP2C9IM (n = 12; 9 and 3 carriers of CYP2C9*1/*3 and *1/*13, respectively). Zafirlukast concentrations were determined using a validated HPLC-MS/MS analytical method in plasma samples collected after the drug intake. Compared with the CYP2C9EM group, the Cmax and AUCinf of Zafirlukast in the CYP2C9IM group were 1.44- and 1.70-fold higher, respectively (p < 0.01 and p < 0.0001). The CL/F of Zafirlukast was 42.8 % lower in the CYP2C9IM group compared with the CYP2C9EM group (p < 0.001). Slightly higher Cmax and AUC, and lower CL/F of Zafirlukast were observed in subjects with the CYP2C9*1/*13 genotype compared with the CYP2C9*1/*3 genotype subjects. CYP2C9*3 and CYP2C9*13 alleles significantly affected the plasma concentrations of Zafirlukast.
